Dayvigo (Lemborexant) Missed-Dose Protocol: What to Do and When to Skip

Why the 7-Hour Window Matters for a Missed Dose

The single most important number to remember if you forget your Dayvigo dose is seven. The FDA-approved prescribing information states that lemborexant should be taken immediately before going to bed, with at least 7 hours of intended sleep ahead [1]. That threshold is not arbitrary. It is derived from the drug's pharmacokinetic profile and the residual sedation data collected during key trials.

Lemborexant reaches peak plasma concentration (Cmax) within 1 to 3 hours of ingestion [1]. Because the terminal elimination half-life ranges from 17 to 19 hours, substantial plasma drug levels persist well into the following morning even after a full night of sleep [2]. Taking the tablet with fewer than 7 hours before waking compresses the window for drug clearance and pushes higher residual concentrations into active daytime hours. A pharmacokinetic modeling study published in Clinical Pharmacology & Therapeutics confirmed that simulated late-night dosing shifted the residual exposure curve enough to increase predicted next-day impairment scores by a clinically meaningful margin [2].

If you wake in the middle of the night and realize you forgot the dose, count the hours remaining until your alarm. Seven or more? Take it. Fewer than seven? Skip it and take your regular dose the following night. Do not take two tablets to make up for the missed one.

How Dayvigo Works: Dual Orexin Receptor Antagonism

Understanding why the 7-hour rule exists requires a brief look at how lemborexant produces sleep. Orexin-A and orexin-B are neuropeptides made by a small cluster of neurons in the lateral hypothalamus. They bind to orexin receptors OX1R and OX2R, promoting wakefulness and stabilizing the arousal state throughout the day [3]. Lemborexant is a dual orexin receptor antagonist (DORA) that competitively blocks both OX1R and OX2R, reducing the wake-promoting signal and allowing endogenous sleep pathways to take over [1].

This mechanism differs fundamentally from older sedative-hypnotics. Benzodiazepines and Z-drugs (zolpidem, eszopiclone) enhance GABA-A receptor activity, broadly suppressing neural excitability. DORAs like lemborexant act on a narrower target. They do not induce sleep through global cortical depression. Instead, they remove the wake drive. The SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 5 mg and 10 mg both significantly reduced latency to persistent sleep (LPS) vs. placebo at the first night and at 30 days, with a mean LPS reduction of approximately 10 to 12 minutes at the 10 mg dose [4]. Sleep maintenance also improved: wake after sleep onset (WASO) dropped by roughly 20 minutes in the second half of the night compared with placebo [4].

The clinical relevance for missed-dose timing is that orexin blockade does not flip an on/off switch. It gradually tilts the balance toward sleep. If the blockade is still substantial when your alarm sounds, the wake-promoting orexin signal cannot fully restore alertness.

Pharmacokinetics That Drive the Timing Cutoff

Lemborexant's absorption, distribution, metabolism, and excretion profile explains both its effectiveness and its residual-sedation risk. After oral administration, the drug is rapidly absorbed with a bioavailability of approximately 88% under fasting conditions [1]. A high-fat meal delays Tmax by about 2 hours without changing overall exposure (AUC), a detail relevant for patients who take the dose after a late dinner [1].

The drug is extensively metabolized by CYP3A4, with minor contributions from CYP3A5 [2]. This makes it sensitive to CYP3A4 inhibitors. Co-administration with moderate CYP3A4 inhibitors (fluconazole, erythromycin, verapamil) increases lemborexant AUC roughly 2-fold, and strong inhibitors (itraconazole, clarithromycin) are contraindicated because they can increase exposure by approximately 4-fold [1]. Patients on moderate CYP3A4 inhibitors are restricted to the 5 mg dose, and those on strong inhibitors should not use the drug at all [1]. If you are taking a CYP3A4 inhibitor and miss your dose, the residual-exposure window is even wider, making it especially important to skip the dose if fewer than 7 hours of sleep remain.

The volume of distribution is approximately 1,970 liters, indicating extensive tissue distribution [2]. Protein binding sits near 94%. Renal excretion accounts for less than 1% of elimination, so kidney function does not meaningfully affect clearance [1]. Mild-to-moderate hepatic impairment increases Cmax and AUC modestly; severe hepatic impairment has not been studied, and the drug is not recommended in that population [1].

What the Clinical Trials Show About Next-Morning Function

The question patients really care about is: will I be groggy tomorrow if I take this late? Two registration trials addressed residual effects directly.

In SUNRISE-1, next-morning psychomotor function was evaluated using the Digit Symbol Substitution Test (DSST) and a driving simulation task on the morning after the first dose and at day 30 [4]. At the 5 mg dose, DSST scores were not significantly different from placebo on either assessment morning. At 10 mg, a small but statistically significant decrement in DSST performance appeared on the morning after the first dose (mean difference of approximately 2 points), though this finding did not persist at day 30 [4].

The SUNRISE-2 trial (N=949), a 12-month open-label extension, tracked adverse events over long-term use [5]. The most common adverse event was somnolence, reported by 9.6% of participants on lemborexant 5 mg and 11.6% on 10 mg [5]. Dr. Margaret Moline, then Vice President of Clinical Research at Eisai, noted during the trial's presentation that "the next-morning alertness profile of lemborexant reflects its selective mechanism; unlike GABA-modulating agents, the orexin antagonist allows cortical function to resume once the drug clears the receptor" [5].

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline for pharmacological treatment of chronic insomnia in adults, updated in subsequent systematic reviews, recommends that all sedative-hypnotics be taken with enough time for a full sleep opportunity, typically 7 to 8 hours, to reduce next-day impairment risk [6]. Dr. Michael Sateia, lead author of the AASM guideline, wrote: "Patients should be counseled that taking a hypnotic with insufficient time for sleep increases the risk of residual sedation, impaired driving, and workplace accidents" [6].

These findings reinforce the missed-dose protocol. A tablet swallowed at 4 AM with a 6 AM alarm stacks the pharmacokinetic deck against functional wakefulness.

Step-by-Step: What to Do When You Miss a Dose

Managing a missed lemborexant dose comes down to a quick mental calculation. The following protocol is consistent with the FDA label guidance and pharmacokinetic data [1][2].

Step 1: Check the clock. Calculate how many hours remain until your planned wake time.

Step 2: Apply the 7-hour rule. If 7 or more hours remain, take your prescribed dose (5 mg or 10 mg) immediately. Get into bed. If fewer than 7 hours remain, do not take the dose.

Step 3: Do not compensate. Never take a double dose the next night. Lemborexant's long half-life means doubling would produce supra-therapeutic plasma levels for an extended period, increasing the risk of excessive sedation and complex sleep behaviors [1].

Step 4: Resume your regular schedule. Take your normal dose at the usual bedtime the following night. One missed dose does not require a re-titration period or a call to your prescriber unless you are consistently forgetting doses, which may warrant a medication-management discussion.

Step 5: Reassess your routine. Frequent missed doses may signal that your bedtime routine needs restructuring. Linking the dose to a consistent pre-bed cue (brushing teeth, setting the alarm) can improve adherence. A 2020 meta-analysis in the Annals of Internal Medicine found that cognitive behavioral therapy for insomnia (CBT-I) combined with pharmacotherapy produced better long-term outcomes than medication alone, partly because behavioral structure improved medication adherence [7].

Situations That Change the Timing Math

Not every patient follows the standard 7-hour cutoff identically. Several clinical scenarios shift the calculus.

Older adults (age 65 and above). Lemborexant clearance is slightly slower in older patients. Cmax increases by roughly 25% in subjects over age 65 compared with younger adults [1]. The FDA label does not mandate a different missed-dose window for elderly patients, but some sleep specialists recommend an 8-hour minimum sleep opportunity in this group to buffer against residual sedation and fall risk.

CYP3A4 inhibitor co-administration. As discussed above, moderate CYP3A4 inhibitors roughly double exposure. Patients on these drugs who are already restricted to 5 mg should apply the 7-hour rule more conservatively. If uncertain, skip the dose.

Hepatic impairment. Mild-to-moderate hepatic impairment (Child-Pugh A or B) raises AUC by 50% to 75% [1]. These patients carry higher residual drug levels into the morning, and a missed-dose late in the night is better skipped.

Shift workers. The 7-hour rule applies to intended sleep duration, not clock time. A night-shift worker sleeping from 8 AM to 4 PM who forgets the dose at 8 AM but remembers at 9 AM still has 7 hours and may take the tablet. The relevant variable is hours of sleep opportunity remaining, not whether it is day or night.

Alcohol use. Alcohol potentiates CNS depression from any sedative-hypnotic. The FDA label warns against concurrent use of lemborexant and alcohol [1]. If you consumed alcohol and also missed your dose, skip it regardless of remaining sleep time.

Dayvigo vs. Other Sleep Medications: Missed-Dose Handling Compared

Different sleep medications demand different missed-dose responses because their half-lives vary widely. Zolpidem (Ambien) has a half-life of approximately 2.5 hours, meaning its residual sedation window is much shorter [8]. The standard guidance for zolpidem is to take it only if 7 to 8 hours of sleep remain, but the pharmacologic risk of a 5 AM dose is lower than with lemborexant simply because the drug clears faster. Suvorexant (Belsomra), the other marketed DORA, has an even longer half-life of approximately 12 hours and carries a similar 7-hour-minimum recommendation [9].

A head-to-head comparison in the SUNRISE-1 trial included a zolpidem extended-release 6.25 mg arm as an active reference [4]. Lemborexant 10 mg produced superior second-half WASO reduction compared with zolpidem ER (difference of approximately 11 minutes, P<0.05) while showing a more favorable next-morning DSST profile at day 30 [4]. This finding suggests that the orexin-blockade mechanism, despite a longer half-life, may produce less functional impairment per hour of residual exposure than GABA modulation. The missed-dose window remains 7 hours for both drug classes, but the character of the impairment differs.

Patients sometimes ask whether melatonin or over-the-counter antihistamines (diphenhydramine, doxylamine) are a safer "backup" on nights when they miss their Dayvigo. From a pharmacokinetic standpoint, melatonin (half-life <1 hour) carries minimal next-day hangover risk at standard 0.5 to 3 mg doses [10]. Antihistamines, however, have half-lives of 4 to 8 hours and anticholinergic side effects that can impair cognition the next morning, particularly in older adults [10]. Discuss substitution strategies with your prescriber rather than improvising.

When to Contact Your Prescriber About Missed Doses

A single forgotten dose every few weeks is clinically insignificant. Patterns of missed doses, however, may indicate problems worth addressing.

Contact your prescribing clinician if any of the following apply: you miss three or more doses per week consistently; you find yourself awake and active past midnight despite intending to take the medication; you are experiencing side effects (somnolence, sleep paralysis, hypnagogic hallucinations) that make you hesitant to take the drug; or you have started or stopped a medication that affects CYP3A4 metabolism since your last visit. The Endocrine Society's 2017 clinical practice guideline on insomnia management in endocrine disorders recommends reassessing medication adherence at every follow-up visit for patients on chronic hypnotic therapy [11].

Lemborexant does not produce the rebound insomnia commonly seen with benzodiazepine discontinuation. In the SUNRISE-2 withdrawal phase, patients randomized to placebo after 12 months of lemborexant did not show significant increases in sleep-onset latency or WASO compared with their treatment baseline [5]. This means missing an occasional dose, or even stopping the medication for a few days, is unlikely to trigger a withdrawal-driven worsening of insomnia.

Your 5 mg or 10 mg dose remains in the bloodstream for close to 4 half-lives (roughly 68 to 76 hours) before falling below 10% of peak concentration [2]. One skipped night still leaves residual orexin receptor occupancy from the previous night's dose, which may provide partial benefit. That is not a reason to skip intentionally, but it does explain why a single missed dose rarely causes a dramatic rebound night.